O Brien Greene & Co. Inc Increases Stock Position in Danaher Co. (NYSE:DHR)

O Brien Greene & Co. Inc boosted its position in Danaher Co. (NYSE:DHR) by 0.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 36,209 shares of the conglomerate’s stock after purchasing an additional 184 shares during the period. Danaher comprises 2.7% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 12th biggest position. O Brien Greene & Co. Inc’s holdings in Danaher were worth $8,312,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kovack Advisors Inc. grew its position in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Gilbert & Cook Inc. grew its holdings in Danaher by 2.5% during the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares in the last quarter. Grimes & Company Inc. increased its position in shares of Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after buying an additional 43 shares during the period. Harbour Investments Inc. lifted its stake in Danaher by 3.0% in the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock worth $426,000 after purchasing an additional 45 shares in the last quarter. Finally, Dakota Community Bank & Trust NA boosted its holdings in Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after purchasing an additional 45 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $205.23 on Thursday. The stock has a market capitalization of $148.24 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 2.63 and a beta of 0.83. The firm’s 50-day moving average price is $227.74 and its two-hundred day moving average price is $247.80. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business posted $2.09 earnings per share. As a group, equities analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Analysts Set New Price Targets

DHR has been the topic of a number of recent analyst reports. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group dropped their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Scotiabank started coverage on shares of Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $278.00.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.